While conventional VSV-G–pseudotyped lentiviral vectors offer high transduction efficiency, their broad tropism may result in non-specific transduction. Genevoyager’s proprietary envelope engineering technology is specifically designed to address this challenge by enabling precise and targeted gene delivery:

De-targeting: Specific amino acid mutations are introduced into envelope glycoproteins such as VSV-G and Cocal-GP. While preserving their membrane fusion functionality, these modifications effectively eliminate native receptor binding, thereby reducing off-target transduction

Re-targeting: The modified envelope surface is further engineered to display T cell–specific ligands or antibodies (e.g., CD3-scFv, CD7-scFv), enabling precise targeting and high-efficiency gene delivery to T cells.

Our expertise in downstream purification of enveloped viral vectors ensures the preservation of maximal product potency and efficacy throughout the manufacturing process.

Genevoyager Proprietary Patent: High-Efficiency, T Cell-Specific Lentiviral Envelope

Jurkat: Human acute T lymphoblastic leukemia cell line (CD3⁺)

Nalm-6: Human B lymphoblastic leukemia cell line (CD3⁻)

Mut1, Mut2, Mut3: Proprietary VSV-G mutants developed by Genevoyager with abolished native tropism (“de-targeted”)

Improved HEK293 Production System for Lentiviral Vector Scale-up Manufacturing

Higher Infectious Titer in the Supernatant

By systematically optimizing key process parameters — such as transfection reagents, feeding strategies, DNA input ratios, and packaging plasmid ratios — the optimal packaging conditions were established, increasing the infectious titer in the supernatant to 2×108  TU/mL, representing more than a threefold improvement compared with pre-optimization levels.

Through Optimization of the Process, Final Lentiviral Recovery Reached 25.44% for Physical Titer and 30.37% for Infectious Titer

Through systematic optimization of key parameters—including protectant screening, sample concentration processes, selection of membrane materials and molecular weight cut-off, and overall process control—final lentiviral recovery reached 25.44% for physical titer and 30.37% for infectious titer.